Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases
International Journal of Molecular Sciences · 03.03.2024 · 25 (5) · 2945
DOI: 10.3390/ijms25052945 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.03.2024. Verfasst von Toru Yamashita und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, …. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Neuroprotective Agents. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid for Scientific Research, Challenging Research, Research Committees (Toba K. and Tsuji S.) of the Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
The brain is susceptible to oxidative stress, which is associated with various neurological diseases. Edaravone (MCI-186, 3-methyl-1 pheny-2-pyrazolin-5-one), a free radical scavenger, has promising effects by quenching hydroxyl radicals (∙OH) and inhibiting both ∙OH-dependent and ∙OH-independent lipid peroxidation. Edaravone was initially developed in Japan as a neuroprotective agent for acute cerebral infarction and was later applied clinically to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. There is accumulating evidence for the therapeutic effects of edaravone in a wide range of diseases related to oxidative stress, including ischemic stroke, ALS, Alzheimer’s disease, and placental ischemia. These neuroprotective effects have expanded the potential applications of edaravone. Data from experimental animal models support its safety for long-term use, implying broader applications in various neurodegenerative diseases. In this review, we explain the unique characteristics of edaravone, summarize recent findings for specific diseases, and discuss its prospects for future therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
- Department of Neurology, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
Förderung
- Grant-in-Aid for Scientific Research
- Challenging Research
- Research Committees (Toba K. and Tsuji S.) of the Japan Agency for Medical Research and Development
Zitieren
APA
Yamashita, T., & Abe, K. (2024). Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases. International Journal of Molecular Sciences, 25(5), 2945. https://doi.org/10.3390/ijms25052945
Vancouver
Yamashita T, Abe K. Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases. International Journal of Molecular Sciences. 2024;25(5):2945. doi:10.3390/ijms25052945
BibTeX
@article{Yamashita2024,
author = {Yamashita, Toru and Abe, Koji},
title = {Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {5},
pages = {2945},
doi = {10.3390/ijms25052945}
}
EUVIMED